Eris Lifesciences Limited has informed the Exchange about Action(s) taken or orders passed
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences has been fined ₹65,000 each by BSE and NSE (total ₹1,30,000) for non-compliance with Regulation 17(1) of the SEBI Listing Regulations, which deals with the composition of the Board of Directors. The non-compliance was due to the completion of the term of an Independent Director, leaving a vacancy on the board. The company states it is actively screening suitable candidates to fill the anticipated Independent Director position and expects to report compliance soon. The financial impact is limited to the penalty amount, with no impact on operations or other activities of the company.
The penalty amount is immaterial (₹1.30 lakh total) and unlikely to affect the stock price. The key concern is board composition compliance, which the company is working to resolve shortly, reducing any lingering governance risk.